Category: Cancer Treatments

Home / Cancer Treatments

Categories

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat ...

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products....

JW Therapeutics Announces That Its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

SHANGHAI, CHINA, November 9, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy pr...

JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T-cell-based Immunotherapies

SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and com...

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy p...

How China is leading the development of CAR T-Cell therapy?

March 2023: CAR-T-cell therapy is a novel and effective cancer treatment modality that has revolutionized the treatment of cancer, particularly blood cancers. This therapy achieves a therapeutic eff...

Cargo, a cancer drug startup, raises $200 million to combat CAR-T relapse

March 2023: Several types of lymphoma, as well as certain leukaemias and multiple myeloma, can now be effectively treated with CAR-T therapy. Recent studies have demonstrated the efficacy of CAR-T th...

New CAR T-Cell therapy drug in lupus renaissance

Feb 2024: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a "renaissance" for lupus, according to a speaker at the symposium Basic and Cl...

Kite completes acquisition of Tmunity

Press Release Feb 2023: - Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical...

High CR rates are overcome by CD22-directed CAR T-Cell therapy against CD19 relapse in LBCL

In February 2023, a phase 1 trial at a single institution found that it was safe and possible for people with heavily pretreated large B-cell lymphoma (LBCL) to use CD22-directed chimeric antigen rec...

Scan the code